Compare CLGN & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLGN | CELU |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 50.7M |
| IPO Year | N/A | N/A |
| Metric | CLGN | CELU |
|---|---|---|
| Price | $1.82 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $11.50 | $6.00 |
| AVG Volume (30 Days) | 20.8K | ★ 61.1K |
| Earning Date | 11-26-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,475,000.00 | ★ $40,578,000.00 |
| Revenue This Year | $1,617.28 | N/A |
| Revenue Next Year | $83.54 | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 280.77 | N/A |
| 52 Week Low | $1.31 | $1.00 |
| 52 Week High | $4.98 | $4.35 |
| Indicator | CLGN | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 33.82 |
| Support Level | $1.77 | $1.62 |
| Resistance Level | $1.93 | $2.01 |
| Average True Range (ATR) | 0.15 | 0.13 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 10.20 | 2.82 |
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.